Home
AMGN
AMGN News

Latest Amgen Inc. (AMGN) News on September 15, 2025

Morningstar Research

2 days ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Argus Research

3 days ago

Analyst Report: AMGEN Inc.

Argus Research

3 days ago

Market Digest: AMGN, APD, PCG, RL, SJM, DG

Amgen Inc (AMGN) Releases Top-Line Results From ASCEND Study of Rocatinlimab

Insider Monkey

4 days ago

Amgen Inc (AMGN) Releases Top-Line Results From ASCEND Study of Rocatinlimab

Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study

Simply Wall St.

5 days ago

Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study

Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care

PR Newswire

5 days ago

Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership

BioPharma Dive

5 days ago

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership

The Bull Case For Amgen (AMGN) Could Change Following Phase 3 Rocatinlimab Data Release

Simply Wall St.

5 days ago

The Bull Case For Amgen (AMGN) Could Change Following Phase 3 Rocatinlimab Data Release

MT Newswires

5 days ago

Trump Signs Memorandum to Crack Down on Misleading Direct-to-Consumer Drug Ads

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Benzinga

6 days ago

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial

Clinical Trials Arena

6 days ago

Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

GlobeNewswire

6 days ago

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today

Motley Fool

6 days ago

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today

Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

6 days ago

Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

William Blair Reiterates a Buy on Amgen Inc (AMGN)

Insider Monkey

8 days ago

William Blair Reiterates a Buy on Amgen Inc (AMGN)

How Much Would It Take To Earn $100 A Month From Amgen Stock

Benzinga

10 days ago

How Much Would It Take To Earn $100 A Month From Amgen Stock

AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

PR Newswire

10 days ago

AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

Nvidia Invests in Honeywell’s Quantinuum. What It Means for D-Wave, IonQ, and Quantum Stocks.

Barrons.com

11 days ago

Nvidia Invests in Honeywell’s Quantinuum. What It Means for D-Wave, IonQ, and Quantum Stocks.

Biotech company Amgen set to build $600-million research center in Thousand Oaks

LA Times

11 days ago

Biotech company Amgen set to build $600-million research center in Thousand Oaks

Why Is Sanofi Stock Falling Thursday?

Benzinga

11 days ago

Why Is Sanofi Stock Falling Thursday?

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Insider Monkey

11 days ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Nvidia Investment In Honeywell's Quantinuum Sends Quantum Computing Stocks Up

Investor's Business Daily

11 days ago

Nvidia Investment In Honeywell's Quantinuum Sends Quantum Computing Stocks Up

MT Newswires

11 days ago

Honeywell-Backed Quantinuum Receives Funding From Nvidia

Business Wire

11 days ago

FUJIFILM Biotechnologies Welcomes Samuel Hernandez as Site Head of Texas Facility

Amgen (AMGN) Unveils US$600 Million Innovation Hub Expanding R&D Efforts in California

Simply Wall St.

12 days ago

Amgen (AMGN) Unveils US$600 Million Innovation Hub Expanding R&D Efforts in California

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Zacks

12 days ago

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

MT Newswires

12 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

13 days ago

Sector Update: Health Care Stocks Retreat Tuesday Afternoon

MT Newswires

13 days ago

Sector Update: Health Care

Leerink Partners Maintains a Hold on Amgen (AMGN)

Insider Monkey

13 days ago

Leerink Partners Maintains a Hold on Amgen (AMGN)

Nio, Signet Jewelers, Amgen: Trending Tickers

Yahoo Finance Video

13 days ago

Nio, Signet Jewelers, Amgen: Trending Tickers

MT Newswires

13 days ago

Amgen to Invest Over $600 Million in Science and Innovation Center at California HQ

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

PR Newswire

13 days ago

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Amgen Inc. (AMGN)’s Experimental Obesity Drug MariTide Shows Up to 20% Weight Loss Potential

Insider Monkey

13 days ago

Amgen Inc. (AMGN)’s Experimental Obesity Drug MariTide Shows Up to 20% Weight Loss Potential

Here’s What Jim Cramer Wishes Amgen Inc. (AMGN) Should Do To Its Drug That Hurts Like A “Banshee”

Insider Monkey

13 days ago

Here’s What Jim Cramer Wishes Amgen Inc. (AMGN) Should Do To Its Drug That Hurts Like A “Banshee”

Is Amgen Stock Underperforming the S&P 500?

Barchart

14 days ago

Is Amgen Stock Underperforming the S&P 500?

Here's Why Amgen (AMGN) is a Strong Value Stock

Zacks

14 days ago

Here's Why Amgen (AMGN) is a Strong Value Stock

2 Profitable Stocks Worth Your Attention and 1 We Avoid

StockStory

14 days ago

2 Profitable Stocks Worth Your Attention and 1 We Avoid

Piper Sandler Lifts PT on Amgen (AMGN) to $342 From $328, Keeps an Overweight Rating

Insider Monkey

15 days ago

Piper Sandler Lifts PT on Amgen (AMGN) to $342 From $328, Keeps an Overweight Rating

With 81% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners

Simply Wall St.

16 days ago

With 81% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

Simply Wall St.

16 days ago

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

PR Newswire

16 days ago

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill

Insider Monkey

17 days ago

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase

Insider Monkey

17 days ago

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase

MT Newswires

17 days ago

DBS Bank Adjusts Amgen Price Target to $360 From $365, Maintains Buy Rating

Amgen partners with Veeva Systems to enhance clinical trial processes

Clinical Trials Arena

17 days ago

Amgen partners with Veeva Systems to enhance clinical trial processes

MT Newswires

18 days ago

Veeva Systems, Amgen Collaborate to Further Streamline Clinical Trials

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation

PR Newswire

18 days ago

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation

2 Dividend Stocks to Hold for the Next 10 Years

Motley Fool

18 days ago

2 Dividend Stocks to Hold for the Next 10 Years

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

GlobeNewswire

19 days ago

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management

Simply Wall St.

20 days ago

Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Zacks

20 days ago

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Dow Loses About 350 Points After Record-Breaking Run

The Wall Street Journal

20 days ago

Dow Loses About 350 Points After Record-Breaking Run

Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

Simply Wall St.

21 days ago

Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

Benzinga

21 days ago

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

MT Newswires

21 days ago

Amgen Says US FDA Broadens Approved Use of Repatha

MT Newswires

21 days ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

Zacks

21 days ago

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

PR Newswire

21 days ago

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

MT Newswires

21 days ago

Update: BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug

Reuters

21 days ago

Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug

MT Newswires

21 days ago

BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

GlobeNewswire

21 days ago

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Business Wire

21 days ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

MT Newswires

21 days ago

Piper Sandler Adjusts Price Target on Amgen to $342 From $328, Maintains Overweight Rating

Investing in Amgen (NASDAQ:AMGN) three years ago would have delivered you a 35% gain

Simply Wall St.

24 days ago

Investing in Amgen (NASDAQ:AMGN) three years ago would have delivered you a 35% gain

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Zacks

24 days ago

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment

Exec Edge

24 days ago

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

25 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Zacks

25 days ago

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

PR Newswire

25 days ago

SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

Cytokinetics Names Jim Daly to Board of Directors

GlobeNewswire

a month ago

Cytokinetics Names Jim Daly to Board of Directors

MT Newswires

a month ago

Rothschild & Co Redburn Adjusts Price Target on Amgen to $180 From $185, Maintains Sell Rating

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade

Motley Fool

a month ago

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Business Wire

a month ago

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet

Simply Wall St.

a month ago

Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet

SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease

Zacks

a month ago

SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease

MT Newswires

a month ago

Daiwa Securities Adjusts Price Target on Amgen to $310 From $350, Maintains Outperform Rating

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Zacks

a month ago

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'

Investor's Business Daily

a month ago

Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'

MT Newswires

a month ago

Bernstein Adjusts Price Target on Amgen to $335 From $350

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

GlobeNewswire

a month ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call

StockStory

a month ago

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

StockStory

a month ago

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Pharma Voice

a month ago

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer

Insider Monkey

a month ago

Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

Zacks

a month ago

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks

a month ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution

Simply Wall St.

a month ago

Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Zacks

a month ago

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Barrons.com

a month ago

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Zacks

a month ago

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

MT Newswires

a month ago

HSBC Adjusts Amgen Price Target to $343 From $337, Maintains Buy Rating

Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years

Simply Wall St.

a month ago

Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

Investor's Business Daily

a month ago

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

NRG Energy, Amgen, Arista Networks: Trending Tickers

Yahoo Finance Video

a month ago

NRG Energy, Amgen, Arista Networks: Trending Tickers

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Benzinga

a month ago

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Teva’s Ajovy becomes first migraine prevention drug approved for children

Pharmaceutical Technology

a month ago

Teva’s Ajovy becomes first migraine prevention drug approved for children

MT Newswires

a month ago

UBS Cuts Price Target on Amgen to $317 From $326, Maintains Neutral Rating

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

Zacks

a month ago

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

Share on Social Networks: